Research ArticleOriginal Article
Open Access

Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor

Maizatul A. Othman, Wan Syamimee W. Ghazali, Wan Zuraida W. A. Hamid, Kah K. Wong and Nurul K. Yahya
Saudi Medical Journal August 2017, 38 (9) 934-941; DOI: https://doi.org/10.15537/smj.2017.9.20841

References

  1. ↵
    1. Scott DL,
    2. Wolfe F,
    3. Huizinga TW
    (2010) Rheumatoid arthritis. Lancet 376:1094–108.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Verheul M,
    2. Fearon U,
    3. Trouw L,
    4. Veale D
    (2015) Biomarkers for rheumatoid and psoriatic arthritis. Clin Immunol 161:2–10.
    OpenUrlCrossRef
  3. ↵
    1. Cross M,
    2. Smith E,
    3. Hoy D,
    4. Carmona L,
    5. Wolfe F,
    6. Vos T,
    7. et al.
    (2014) The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 73:1316–1322.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Aletaha D,
    2. Neogi T,
    3. Silman AJ,
    4. Funovits J,
    5. Felson DT,
    6. Bingham CO,
    7. et al.
    (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Jaskowski TD,
    2. Hill HR,
    3. Russo KL,
    4. Lakos G,
    5. Szekanecz Z,
    6. Teodorescu M
    (2010) Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies. J Rheumatol 37:1582–1588.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Majka DS,
    2. Deane KD,
    3. Parrish LA,
    4. Lazar AA,
    5. Barón AE,
    6. Walker CW,
    7. et al.
    (2008) Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis 67:801–807.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Nielen MM,
    2. van Schaardenburg D,
    3. Reesink HW,
    4. Van de Stadt RJ,
    5. van der Horst-Bruinsma IE,
    6. de Koning MH,
    7. et al.
    (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Firestein GS
    (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356–361.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Ning X,
    2. Jian Z,
    3. Wang W
    (2015) Low Serum Levels of Interleukin 35 in Patients with Rheumatoid Arthritis. Tohoku J Exp Med 237:77–82.
    OpenUrl
  10. ↵
    1. van der Helm-van AH,
    2. Mil KNV,
    3. Breedveld FC,
    4. Toes R,
    5. Huizinga T
    (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7:R949–R58.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Forslind K,
    2. Ahlmén M,
    3. Eberhardt K,
    4. Hafström I,
    5. Svensson B
    (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Conigliaro P,
    2. Chimenti M,
    3. Triggianese P,
    4. Sunzini F,
    5. Novelli L,
    6. Perricone C,
    7. et al.
    (2016) Autoantibodies in inflammatory arthritis. Autoimmun Rev 15:673–683.
    OpenUrl
  13. ↵
    1. Montes A,
    2. Regueiro C,
    3. Perez-Pampin E,
    4. Boveda MD,
    5. Gomez-Reino JJ,
    6. Gonzalez A
    (2016) Anti-Carbamylated Protein Antibodies as a Reproducible Independent Type of Rheumatoid Arthritis Autoantibodies. PLoS One 11:e0161141.
    OpenUrl
  14. ↵
    1. Shi J,
    2. Knevel R,
    3. Suwannalai P,
    4. van der Linden MP,
    5. Janssen GM,
    6. van Veelen PA,
    7. et al.
    (2011) Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 108:17372–17377.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Jiang X,
    2. Trouw LA,
    3. van Wesemael TJ,
    4. Shi J,
    5. Bengtsson C,
    6. Källberg H,
    7. et al.
    (2014) Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis 73:1761–1768.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Verheul M,
    2. van Erp S,
    3. van der Woude D,
    4. Levarht E,
    5. Mallat M,
    6. Verspaget H,
    7. et al.
    (2016) Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation;renal failure, smoking and chronic inflammation. Ann Rheum Dis 0:1–2.
  17. ↵
    1. Shi J,
    2. van Veelen PA,
    3. Mahler M,
    4. Janssen GM,
    5. Drijfhout JW,
    6. Huizinga TW,
    7. et al.
    (2014) Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev 13:225–230.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Burska AN,
    2. Hunt L,
    3. Boissinot M,
    4. Strollo R,
    5. Ryan BJ,
    6. Vital E,
    7. et al.
    (2014) Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm 2014.
  19. ↵
    1. Mydel P,
    2. Wang Z,
    3. Brisslert M,
    4. Hellvard A,
    5. Dahlberg LE,
    6. Hazen SL,
    7. et al.
    (2010) Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol 184:6882–6890.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Kalim S,
    2. Karumanchi SA,
    3. Thadhani RI,
    4. Berg AH
    (2014) Protein carbamylation in kidney disease: pathogenesis and clinical implications. Am J Kidney Dis 64:793–803.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Shi J,
    2. van de Stadt LA,
    3. Levarht E,
    4. Huizinga TW,
    5. Toes RE,
    6. Trouw LA,
    7. et al.
    (2013) Anti–Carbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. Arthritis Rheum 65:911–915.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Ajeganova S,
    2. Humphreys J,
    3. Verheul M,
    4. van Steenbergen H,
    5. van Nies J,
    6. Hafström I,
    7. et al.
    (2016) Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Ann Rheum Dis 75:1924–1932.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Chimenti MS,
    2. Triggianese P,
    3. Nuccetelli M,
    4. Terracciano C,
    5. Crisanti A,
    6. Guarino MD,
    7. et al.
    (2015) Auto-reactions, autoimmunity and psoriatic arthritis. Autoimmun Rev 14:1142–1146.
    OpenUrl
  24. ↵
    1. Fransen J,
    2. Stucki G,
    3. van Riel PL
    (2003) Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Care Res 49:S214–S224.
    OpenUrlCrossRef
  25. ↵
    1. Sahin O,
    2. Kaptanoglu E,
    3. Bakici MZ,
    4. Sezer H,
    5. Elden H,
    6. Hizmetli S
    (2011) Diagnostic value of autoantibodies against citrullinated peptide antigens in rheumatoid arthritis: comparison of different commercial kits/romatoid artritte sitrulinli peptit antikorlarinin tanisal degeri: farkli ticari kitlerin karsilastirilmasi. Turk J Rheumatol 26:13–19.
    OpenUrl
  26. ↵
    1. Fries JF,
    2. Spitz P,
    3. Kraines RG,
    4. Holman HR
    (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Wong KK,
    2. Ch’ng ES,
    3. Loo SK,
    4. Husin A,
    5. Muruzabal MA,
    6. Møller MB,
    7. et al.
    (2015) Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. Exp Mol Pathol 99:537–545.
    OpenUrl
  28. ↵
    1. Ruopp MD,
    2. Perkins NJ,
    3. Whitcomb BW,
    4. Schisterman EF
    (2008) Youden Index and Optimal Cut-Point Estimated from Observations Affected by a Lower Limit of Detection. Biom J 50:419–430.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Challener GJ,
    2. Jones JD,
    3. Pelzek AJ,
    4. Hamilton BJ,
    5. Boire G,
    6. de Brum-Fernandes AJ,
    7. et al.
    (2016) Anti-carbamylated Protein Antibody Levels Correlate with Anti-Sa (Citrullinated Vimentin) Antibody Levels in Rheumatoid Arthritis. J Rheumatol 43:273–281.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Scinocca M,
    2. Bell DA,
    3. Racapé M,
    4. Joseph R,
    5. Shaw G,
    6. McCormick JK,
    7. et al.
    (2014) Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. J Rheumatol 41:270–279.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Yee A,
    2. Webb T,
    3. Seaman A,
    4. Infantino M,
    5. Meacci F,
    6. Manfredi M,
    7. et al.
    (2015) Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunol Res 61:24–30.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Shi J,
    2. van de Stadt LA,
    3. Levarht EN,
    4. Huizinga TW,
    5. Hamann D,
    6. van Schaardenburg D,
    7. et al.
    (2014) Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 73:780–783.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Brink M,
    2. Verheul MK,
    3. Rönnelid J,
    4. Berglin E,
    5. Holmdahl R,
    6. Toes RE,
    7. et al.
    (2015) Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther 17:25.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Verheul MK,
    2. Shiozawa K,
    3. Levarht EN,
    4. Huizinga TW,
    5. Toes RE,
    6. Trouw LA,
    7. et al.
    (2015) Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent. Rheumatology (Oxford) 54:1930–1932.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Alessandri C,
    2. Bartosiewicz I,
    3. Pendolino M,
    4. Mancini R,
    5. Colasanti T,
    6. Pecani A,
    7. et al.
    (2015) Anti-carbamylated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients: lack of correlation with anti-cyclic citrullinated protein antibodies and rheumatoid factor. Clin Exp Rheumatol 33:824–830.
    OpenUrl
  36. ↵
    1. Humphreys JH,
    2. Verheul MK,
    3. Barton A,
    4. MacGregor AJ,
    5. Lunt M,
    6. Toes RE,
    7. et al.
    (2015) Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 0:1–6.
  37. ↵
    1. Martínez G,
    2. Gómez JA,
    3. Bang H,
    4. Martínez-Gamboa L,
    5. Roggenbuck D,
    6. Burmester G-R,
    7. et al.
    (2016) Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients. Rheumatol Int 36:781–791.
    OpenUrlPubMed
  38. ↵
    1. Albers H,
    2. Brinkman D,
    3. Kamphuis S,
    4. van Suijlekom-Smit L,
    5. van Rossum M,
    6. Hoppenreijs E,
    7. et al.
    (2010) Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis. Arthritis Care Res 62:204–212.
    OpenUrlWeb of Science
  39. ↵
    1. Šenolt L,
    2. Grassi W,
    3. Szodoray P
    (2014) Laboratory biomarkers or imaging in the diagnostics of rheumatoid arthritis? BMC Med 12:49.
    OpenUrl
  40. ↵
    1. Barra L,
    2. Pope JE,
    3. Orav JE,
    4. Boire G,
    5. Haraoui B,
    6. Hitchon C,
    7. et al.
    (2014) Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol 41:2361–2369.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Nell V,
    2. Machold KP,
    3. Stamm TA,
    4. Eberl G,
    5. Heinzl H,
    6. Uffmann M,
    7. et al.
    (2005) Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731–1736.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Crowson CS,
    2. Rahman MU,
    3. Matteson EL
    (2009) Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol 36:1606–1610.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Yildirim K,
    2. Karatay S,
    3. Melikoglu MA,
    4. Gureser G,
    5. Ugur M,
    6. Senel K
    (2004) Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci 34:423–426.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Gomez EL,
    2. Gun SC,
    3. Somnath SD,
    4. D’souza B,
    5. Lim AL,
    6. Chinna K,
    7. et al.
    (2011) The prevalence of rheumatoid factor isotypes and anti-cyclic citrullinated peptides in Malaysian rheumatoid arthritis patients. Int J Rheum Dis 14:12–17.
    OpenUrlPubMed
  45. ↵
    1. Gomez EL,
    2. Gun SC,
    3. Somanath SD,
    4. Chinna K,
    5. Radhakrishnan AK
    (2013) Ethnic differences in the prognostic utility of rheumatoid factor isotypes and anticyclic citrullinated peptides in rheumatoid arthritis patients: a cross-sectional study. Mod Rheumatol 23:716–721.
    OpenUrl
  46. ↵
    1. van Wesemael TJ,
    2. Ajeganova S,
    3. Humphreys J,
    4. Terao C,
    5. Muhammad A,
    6. Symmons DP,
    7. et al.
    (2016) Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Res Ther 18:285.
    OpenUrl
  47. ↵
    1. Too CL,
    2. Yahya A,
    3. Murad S,
    4. Dhaliwal JS,
    5. Larsson PT,
    6. Muhamad NA,
    7. et al.
    (2012) Smoking interacts with HLA-DRB1 shared epitope in the development of anti-citrullinated protein antibody-positive rheumatoid arthritis: results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA). Arthritis Res Ther 14:R89.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Mikuls TR,
    2. Hughes LB,
    3. Westfall AO,
    4. Holers VM,
    5. Parrish L,
    6. van der Heijde D,
    7. et al.
    (2008) Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Ann Rheum Dis 67:1529–1534.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section